Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis over up to 3 years.

Luca MastorinoPaolo DapavoLorenza BurziFrancois RossetIsotta di Giunipero di CorteranzoFrancesco LeoAnna VerroneElena StroppianaMichela OrtoncelliSimone RiberoPietro Quaglino

Published in: International journal of dermatology (2024)

Our study confirms the good effectiveness and favorable safety profile of brodalumab in a real-world setting over up to 3 years of treatment.

Keyphrases

randomized controlled trial
early onset
high intensity
electronic health record